⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
AAV-Follistatin Gene Therapy
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-03 — Myostatin inhibitors and the paradox of larger but weaker muscles: cross-connection with myostatin-inhibitors: Follistatin gene therapy acts via myostatin/activin blockade and inherits the same mass-vs-strength uncoupling concern Attia raises. (novelty: 3)
- 2026-07-13 — CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy: CALM-AF-AI Phase 1/2a open-label trial launched: intramuscular AAV9-follistatin as monotherapy or combined with a VEGF-encoding angiogenesis plasmid, assessing safety/tolerability and preliminary muscle mass and performance signals in age-related muscle loss — first-in-class dual gene-therapy protocol for sarcopenia; no efficacy readout yet. [human-rct] (novelty: 4)
Open questions
Related
Contributing findings
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
13-jul-2026
novelty 4
per-area 4
strengthens